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E sophagogastrectomy is one of the most complex sur-gical procedures performed and therefore has the
potential for high morbidity and mortality rates.1-3 Over
the past 30 years, there have been significant improve-
ments in perioperative management and techniques that
have led to decreases in both morbidity and mortality
rates for elective esophageal resection.4 In addition,
several studies have documented decreased mortality
when complex oncologic procedures, such as pancrea-
tectomy or liver resection, are performed in high-vol-
ume referral centers.5-8 Analysis of a Medicare-linked
database by Begg and colleagues9 revealed a signifi-
cantly decreased operative mortality when pancreatec-
tomy, liver resection, pelvic exenteration, or esophagec-
tomy was performed in an experienced high-volume
Objective: We sought to evaluate the effect of operative volume, hospital
size, and cancer specialization on morbidity, mortality, and hospital use after
esophagectomy for cancer.
Methods: Data derived from the Health Care Utilization Project was used to
evaluate all Medicare-reimbursed esophagectomies for treatment of cancer
from 1994 to 1996 in 13 national cancer institutions and 88 community hos-
pitals. The complications of care, length of stay, hospital charges, and mor-
tality were assessed according to hospital size (≥600 beds vs <600 beds),
cancer specialization (national cancer institution vs community hospital),
and operative volume (esophageal [≥5 Medicare esophagectomies per year
vs <5 Medicare esophagectomies per year] and nonesophageal operations
[≥3333 cases per year vs <3333 cases per year]).
Results: Mortality was lower in national cancer institution hospitals (4.2%
[confidence interval, 2.0%-6.4%] vs 13.3% [confidence interval, 4.2%-
26.2%], P = .05) and in hospitals performing a large number of esophagec-
tomies (3.0% [confidence interval, 0.09%-5.1%] vs 12.2% [confidence inter-
val, 4.5%-19.8%], P < .05). Multivariate analysis revealed that the
independent risk factor for operative mortality was the volume of esophagec-
tomies performed (odds ratio, 3.97; P = .03) and not the number of non-
esophageal operations, hospital size, or cancer specialization. Hospitals per-
forming a large number of esophagectomies also showed a tendency toward
decreased complications (55% vs 68%, P = .06), decreased length of stay
(14.7 days vs 17.7 days, P = .006), and decreased charges ($39,867 vs
$62,094, P < .005).
Conclusions: These results demonstrate improved outcomes and decreased hos-
pital use in hospitals that perform a large number of esophagectomies and sup-
port the concept of tertiary referral centers for such complex oncologic proce-
dures as esophagectomies. (J Thorac Cardiovasc Surg 2000;119:1126-34)
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remain consistent, all P values in the figure, including analy-
ses not related to severity-adjusted data, were represented as
not significant if the P value was less than .05. Multivariate
analysis for the mortality data was performed by logistic
regression, and analysis of hospital charge data was per-
formed by using linear regression. Multivariate analysis was
performed on all variables that we believed had prognostic or
clinical relevance. Statistical packages used included SPSS
(SPSS Inc, Chicago, Ill) and Inforum’s Outcomes Analyst II
(Inforum). 
Results
Characteristics of patients undergoing esophageal
resection. A total of 340 patients were identified who
underwent esophageal resection for cancer in 25 hospi-
tals. Patients with pharyngeal and oral tumors were
excluded to provide a more homogeneous group of
patients. As shown in Table I, the majority (265 [78%])
of patients were male, with an average age of 70.4 ± 6.9
years. The lower esophagus was the predominant loca-
tion with 227 (67%) patients. A total of 196 (58%)
patients underwent a partial esophagectomy (ie, Ivor
Lewis type [right transthoracic] or left transthoracic)
with a chest anastomosis, and 133 (39%) patients
underwent a total esophagectomy (transhiatal or 3-field
esophagectomy) with a cervical anastomosis. In 11
(3%) patients the type of esophagectomy was not spec-
ified. No differences could be noted between types of
hospitals (ie, cancer specialization, hospital size, or
operative volume) according to age, sex, or location of
tumor (data not shown). Some variation was noted
between hospitals and type of procedure, with a higher
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center.9 This study did not, however, evaluate the effect
on hospital use or the role of other hospital factors,
such as cancer specialization (national cancer institu-
tion vs community hospital), hospital size, or volume
of nonesophageal operations. We therefore reviewed
Medicare-reimbursed esophagectomies from data pro-
vided by the Health Care Financing Administration by
means of Inforum, the subsidiary of the Medstat Group,
to determine which hospital factors were most closely
related to short-term outcome and hospital use after
esophageal resection for cancer.
Material and methods
Medstat’s severity-adjustment methodology, developed
with national Health Care Utilization Project (HCUP) data,
was used to evaluate all Medicare-reimbursed esophagec-
tomies for cancer from 1994 to 1996 in 13 national cancer
institutes and 88 community hospitals. Selection criteria for
esophagectomies were based on International Classification
of Diseases, ninth edition (ICD-9), procedure and diagnosis
codes. Patients with malignant disease of the esophagus were
selected, excluding those with oral or pharyngeal tumors. The
total operative volume of each hospital was obtained in a sim-
ilar manner, searching for all major surgical procedure codes.
For the purpose of analysis, hospitals were assessed
according to various factors: esophageal operative volume
(≥5 cases per year vs <5 cases per year), total operative vol-
ume (≥3333 cases per year vs <3333 cases per year), bed size
(≥600 beds vs <600 beds), and cancer specialization (nation-
al cancer institution vs community hospital). The factors were
divided when possible by balancing the number of patients
and hospitals in each category. National cancer institution
versus community hospitals were divided arbitrarily by cate-
gory. Data assessed included sex, age, location of tumor, type
of procedure, operative mortality, complications of care,
length of stay, and hospital charges. Actual data and severity-
adjusted data were analyzed. Severity-adjusted data were
obtained from Inforum Outcomes Analyst, a subsidiary of the
Medstat Group (Nashville, Tenn). All severity-adjusted val-
ues were calculated from algorithms developed from a 10
million–patient database obtained from the National HCUP
survey. These algorithms provided expected values depend-
ing on the individual patient’s age, principal diagnosis, sex,
admission type, and comorbidities.
Statistical analysis was performed on actual and severity-
adjusted data. Differences between the variables were tested
for significance by means of the χ2 analysis for categoric
variables and the Student t test for continuous variables.
Charge and length of stay data were analyzed after log trans-
formation to adjust for skewness. The final data were retrans-
formed for presentation clarity and clinical relevance.
Severity-adjusted data were assessed by using analysis with
population variances provided by Inforum and with resultant
95% confidence intervals (CIs) assessed for statistical signif-
icance at the .05 level. This method did not provide exact P
values for nonsignificant data in the severity-adjusted data. To
Table I.  Characteristics of patients undergoing
esophageal resection for cancer





Cervical esophagus 6 2
Upper esophagus 17 5
Middle esophagus 38 11
Lower esophagus 227 67
Not otherwise specified 52 15
Procedure
Total esophagectomy* 133 39
Partial esophagectomy* 196 58
Not otherwise specified 11 3
Total patients 340
*Total esophagectomy is defined as transhiatal esophagectomy or total
transthoracic esophagectomy (ie, cervical anastomosis), and partial
esophagectomy is defined as right (Ivor Lewis) or left transthoracic
esophagectomy (ie, thoracic anastomosis).
percentage of partial esophagectomies in national can-
cer institutions and high-volume operative centers (data
not shown).
Mortality and complications of care according to
hospital type. The majority of patients tended to be
operated on in national cancer institutions (310 patients
[91%]) and high-volume (>5 esophagectomies per
year, 266 patients [78%]) operative centers (Table II),
although the number of hospitals was evenly distrib-
uted between groups. Operative mortality and compli-
cations of care were assessed either as actual data or as
severity-adjusted data in which an index was created of
actual over expected outcome. In both actual and sever-
ity-adjusted data, mortality was significantly reduced
in national cancer institution hospitals (4.2% [CI,
2.0%-6.4%] vs 13.3% [CI, 4.2%-26.2%], P < .05) and
hospitals that performed a large number of esophagec-
tomies (3.0% [CI, 0.09%-5.1%] vs 12.2% [CI, 4.5%-
19.8%], P = .004). Severity-adjusted data also suggest-
ed that small hospitals (<600 beds) had a lower than
expected mortality index when corrected for associated
comorbidities (0.21 vs 0.62, P < .05). A multivariate
analysis was therefore performed to try to assess the
independent risk factor for mortality (Table III). In this
analysis the volume of esophageal operations per-
formed was the only significant risk factor (odds ratio,
3.97; P = .03) and not the volume of nonesophageal
operations, cancer specialization, or the size of the hos-
pital. Because we had noted a difference in the type of
surgical procedure performed (ie, total vs partial
esophagectomy) between groups, we included this
variable in our univariate and multivariate analysis and
found no relationship (odds ratio, 0.86; P = .81). Fig 1
depicts the linear relationship between hospital
esophageal operative volume and mortality. This analy-
sis shows that the majority of hospitals fall into the cat-
egory of low-volume centers. Analysis by continuous
variables is limited by the large gap between high- and
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Table II. Mortality and complication of care with and without risk stratification in patient undergoing esophageal
resection for cancer according to operative volume, hospital size, and cancer specialization
Actual Actual
mortality/ Actual complications of 
No. of Actual expected complications care/expected 
hospitals Patients mortality* mortality†‡ of care* complications of care†‡
Cancer specialization
National cancer institutions 12 310 13 (4.2%) 0.33 (0.26–0.45) 176 (57%) 2.25 (1.89–2.79)
Community hospitals 13 30 4 (13.3%) 1.01 (0.54–7.63) 21 (70%) 2.66 (1.67–6.61)
P value .05 <.05 NS NS
Esophagectomy volume
≥5 cases/y 5 266 8 (3.0%) 0.23 (0.19–0.33) 147 (55%) 2.18 (1.81–2.75)
<5 cases/y 20 74 9 (12.2%) 0.97 (0.63–2.14) 50 (68%) 2.68 (1.93–4.40)
P value .004 <.05 .06 NS
Total operative volume
≥3333 cases/y 10 263 12 (4.6%) 0.37 (0.29–0.53) 150 (57%) 2.25 (1.86–2.83)
<3333 cases/y 15 77 5 (6.5%) 0.48 (0.32–0.98) 47 (61%) 2.44 (1.76–3.98)
P value NS NS NS NS
Hospital size
≥600 beds 12 176 12 (6.8%) 0.62 (0.44–1.02) 104 (59%) 2.31 (1.85–3.09)
<600 beds 13 164 5 (3.0%) 0.21 (0.16–0.32) 93 (57%) 2.27 (1.79–3.08)
P value NS <.05 NS NS
NS, Not significant.
*Number of patients, with percentage in parentheses.
†Mean with upper and lower 95% CI in parentheses.
‡Ratio of actual mortality or complication/expected mortality or complication obtained by using expected outcomes developed from the 10 million–patient database
of the National HCUP survey.
Table III.  Multivariate analysis of operative 
mortality in hospitals according to operative 
volume, hospital size, or cancer specialization
Hospital factors Odds ratio CIs P value
Mortality
Cancer specialization 0.98 0.23–4.26 .98
(community hospitals)
Esophagectomy 3.97 1.14–13.84 .03
volume (<5 cases/y)
Total operative 1.96 0.32–12.3 .47
volume (<3333 cases/y)
Hospital size (<600 beds) 0.25 0.05–1.31 .10
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low-volume centers and the small number of patients
available for analysis because of the relative rarity of
the disease.
There also appeared to be a trend toward decreased
complications of care in hospitals that performed a
high volume of esophageal operations (55% vs 68%,
P = .06) that was not present in the other hospitals,
although these results were not seen in the severity-
adjusted data. These results suggest that the major
independent risk factor for short-term outcome after
esophageal resection is the number of esophagec-
tomies performed in the hospital and not the amount
of nonesophageal operations, cancer specialization, or
hospital size.
Hospital use according to hospital type.  Length of
stay and hospital charges were evaluated according to
hospital type (Table IV). The data were assessed as
actual data or severity adjusted by subtracting the actu-
al from the expected outcome. There appeared to be
significant differences in hospital charges according to
hospital type, with lower charges noted in national
cancer institution hospitals, high-volume operative
(esophageal or nonesophageal operations) hospitals,
and those with a larger number of beds. Severity-
adjusted data showed that the difference between
expected and actual charges was substantially less in
national cancer institution hospitals and those per-
forming a large number of esophageal or none-
sophageal operations, indicating better management of
resources. A multivariate analysis was therefore per-
formed and revealed that the most significant indepen-
dent risk factor for hospital charges was the volume of
esophageal operations (β = 1.42, P < .003) and the
hospital size (β = 1.29, P < .002).
Assessment of length of stay suggested a difference
according to hospital type when the actual data were
assessed but no difference when severity-adjusted data
were evaluated. These results suggest again that the
most important predictor of decreased hospital use is
esophagectomy volume and not cancer specialization
or volume of nonesophageal operations.
Discussion
Morbidity and mortality rates have decreased dra-
matically over time for esophagectomies performed for
cancer. The mortality rates have dropped from 12% in
the 1970s and early 1980s to 3% in the late 1980s and
early 1990s.4 Furthermore, the number of complica-
tions has decreased from 72% to 60%, with a resultant
decrease in hospital use because of a drop in the num-
ber of days needed to treat resultant complications. The
exact factors in this improvement in short-term out-
come and hospital use are not clear but may be multi-
factorial. One component is surgical expertise because
a large amount of data suggests that morbidity and
mortality can be decreased in complex surgical proce-
dures with experience. This is true in pancreatectomies,
liver resections, lung resections, and colorectal opera-
tions.5-7,10-12 Evidence exists that mortality rates are
reduced for surgeons who perform more of these pro-
cedures. Another component, however, is the improved
perioperative care and patient selection that has come
Fig 1.  Analysis of operative mortality versus hospital esophageal operative volume over the 3-year study period.
The regression equation is as follows: y = 0.113 – 0.00083x (P = .47).
with experience.13,14 This factor may be due to several
things. Hospitals that have a large census (large number
of beds) or perform a large number of operations (not
necessarily esophageal) often are able to purchase
items in bulk at lower cost and have intensive care unit
staff, equipment, and services (epidural-pain service)
unavailable at smaller hospitals. Furthermore, some
hospitals are specialized in oncology (national cancer
institutions) and have a large experience with multidis-
ciplinary efforts, as well as experience with careful
patient selection. One study suggested that even long-
term outcome is affected when patients are cared for by
specialist breast surgeons rather than nonspecialists.15
Gillis and Hole15 noted a 16% reduction in the risk of
dying and an 8% higher survival at 10 years when sim-
ilar patients were cared for by oncologic specialists.
Furthermore, Lee and colleagues16 noted decreased
complications and improved long-term survival when
patients with lung cancer were entered at an experi-
enced oncologic institution in an intergroup trial
(RTOG92-04). Our study therefore evaluated these
other factors (cancer specialization, nonesophageal
operative volume, and hospital size) to determine
whether they were also associated with outcome and
whether improved short-term outcome translated into
decreased hospital use.
We used a Medicare-provided database that assessed
discharge data provided by a large number of institu-
tions. One of the benefits of this database was that it
allowed evaluation of a large number of institutions in
an unbiased fashion. Although the database captured
only Medicare-linked patients, the majority of patients
with esophageal cancer are elderly. Begg and col-
leagues9 noted with another Medicare-linked database
that approximately 90% of patients over 65 years of
age were captured. Additionally, these data were avail-
able not only as actual data but also as risk-stratified
data in which an expected outcome was created on the
basis of the patient’s diagnosis, diagnosis-related
group, age, sex, admission type, and associated comor-
bidities. The risk-stratified data allowed analysis con-
trolled for differences in hospitals’ patient populations
because many tertiary referral centers have reported
that their patients often have more complex disease,
with an increased number of comorbidities.
The major observation of our study was that opera-
tive mortality was dramatically decreased in hospitals
that specialized in cancer care and in hospitals that per-
formed a large number of esophagectomies. Analysis
of the data univariately was difficult because the same
hospitals that specialized in cancer care (national can-
cer institutions) also tended to be the hospitals in which
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Table IV.  Hospital use with and without risk stratification in patients undergoing esophageal resection for cancer
according to operative volume, hospital size, and cancer specialization
Actual length
Actual of stay (d) – Actual Actual hospital
Hospital No. of length expected length hospital charges − expected
factors hospitals Patients of stay (d)* of stay (d)† charges* hospital charges†
Cancer specialization
National cancer institutions 12 310 14.9 (14.1–15.8) 2.3 (1.1–3.6) $42,113 ($39,097–$45,356) $15,812 ($11,872–$19,751) 
Community hospitals 13 30 20.2 (16.1–25.6) 7.0 (2.1–11.9) $67,535 ($50,945–$89,518) $40,629 ($24,978–$56,280)
P value .002 NS <.005 <.05
Esophagectomy volume
≥5 cases/y 5 266 14.7 (13.9–15.6) 2.5 (1.2–3.8) $39,867 ($36,839–$43,144) $14,752 ($10,679–$18,825)
<5 cases/y 20 74 17.7 (15.6–20.2) 3.8 (0.7–6.8) $62,094 ($52,976–$72,773) $29,679 ($19,764–$39,594)
P value .006 NS <.005 <.05
Total operative volume
≥3333 cases/y 10 263 14.8 (13.9–15.7) 2.4 (1.1–3.7) $40,380 ($37,291–$43,726) $14,334 ($10,200–$18,469)
<3333 cases/y 15 77 17.4 (15.2–19.8) 4.0 (1.0–7.0) $58,413 ($49,726–$68,631) $30,524 ($21,072–$39,976)
P value .017 NS <.005 <.05
Hospital size
≥600 beds 12 176 14.1 (13.0–15.2) 1.9 (0.3–3.5) $38,300 ($34,341–$42,715) $15,844 ($10,688–$21,006)
<600 beds 13 164 16.8 (15.6–18.2) 3.7 (1.9–5.6) $50,833 ($46,360–$55,731) $20,315 ($14,572–$26,058)
P value <.05 NS <.05 NS
NS, Not significant.
*Mean with upper and lower 95% CI in parentheses.
†Difference of actual length of stay or hospital charges − expected length of stay or hospital charges obtained by using expected outcomes developed from the 10
million–patient database of the national HCUP survey.
a large number of esophagectomies were performed.
Additionally, in our database few patients underwent
esophagectomies at community hospitals, making a
direct comparison difficult. Multivariate analysis was
therefore performed and suggested that the true inde-
pendent risk factor for operative mortality was the
number of esophagectomies (odds ratio of 3.9, if per-
formed at a low-volume center) and not the specializa-
tion of the hospital (Table III). These findings are cor-
roborated by Begg and colleagues,9 who noted that the
operative mortality in low-volume centers was 17.3%
as opposed to 3.4% in high-volume centers, although
this study did not control for cancer specialization. This
observation has potentially important clinical implica-
tions because it suggests that tertiary referral systems
could be designed for complex oncologic procedures
with low operative mortality that do not necessarily
incorporate cancer specialization. The question
addressed by Gillis and Hole15 and Lee and col-
leagues16 about whether cancer specialization has an
effect on survival still needs to be evaluated in the set-
ting of esophageal cancer. There also appeared to be a
tendency for decreased complications in hospitals in
which a large number of esophagectomies were per-
formed (55% vs 68%, P = .06), although this difference
was not statistically significant when severity-adjusted
data were analyzed. Perhaps a more careful analysis of
morbidity with a delineation of major and minor com-
plications or a larger sample size would allow a statis-
tical difference to be demonstrated.
It is also important to recognize that this database
captured only Medicare-reimbursed esophagectomies,
and we excluded all patients without malignant dis-
ease of the esophagus. In our institution Medicare-
reimbursed cancer-related esophagectomies represent-
ed 37% of all esophagectomies performed. The
number of esophagectomies performed per year is
therefore only a relative value, and the actual threshold
experience level for acceptable mortality is probably
higher when Medicare- and non–Medicare–reim-
bursed esophagectomies for benign and malignant dis-
ease are taken into account. Additionally, as Fig 1
shows, the majority of hospitals in which esophageal
operations are performed fall into the low-volume cat-
egory with high overall mortality rates. Because over-
all survival is low in esophageal cancer (5-year sur-
vival, 20%), all attempts to minimize operative
mortality must be made to realize the benefit of
surgery. As with carotid endarterectomies, esophageal
resection at a center without experienced surgeons
may not be justifiable.17 Further studies need to be
performed to determine whether esophagectomy vol-
ume at the hospital is simply a surrogate end point for
individual surgeon experience or whether this reflects
the experience of the institution at taking care of these
patients with complex diseases.
The second major question was whether the
decreased mortality observed in high-volume centers
translated into decreased hospital use or whether hos-
pital use was determined by other factors. Many cancer
centers have recently adopted multidisciplinary care
centers with pathways for specific procedures in hopes
of improving efficiency and decreasing hospital use,
whereas large hospitals try to decrease costs by pur-
chasing items in bulk or providing efficient multidisci-
plinary intensive care units. Interestingly, univariate
analysis suggested that all these strategies were benefi-
cial, with decreased hospital charges in national cancer
institution hospitals, large hospitals, and hospitals that
perform a large number of operations of either an
esophageal or nonesophageal nature (Table IV).
Multivariate analysis suggested that the most signifi-
cant factors for hospital charges were not only
esophagectomy volume but also size of the hospital
(Table V). These findings imply that hospital charges
can be affected from several directions. Decreased
charges can occur with increased operative experience
and improved short-term outcome, resulting in a
decreased need for hospital care. Alternatively,
decreased charges may be possible by centralizing care
in large hospitals that can deliver services not available
at smaller hospitals. Several studies have suggested that
placement of an epidural catheter appeared to decrease
hospital charges by reducing intensive care and hospi-
tal stays through improved pain control.18-20
Additionally, large hospitals often have available 24-
hour intensive care unit teams not present at smaller
community hospitals.
With our changing patterns of health care, these
observations are important. As health maintenance
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Table V. Multivariate analysis of hospital charges in
hospitals according to operative volume, hospital size,
or cancer specialization
Hospital factors β Coefficient CIs P value
Hospital charges
Cancer specialization 1.18 0.87–1.60 .28
(community hospitals)
Esophagectomy volume 1.42 1.13–1.78 .003 
(<5 cases/y)
Total operative volume 1.03 0.83–1.28 .79 
(<3333 cases/y)
Hospital size (<600 beds) 1.29 1.1–1.53 .002
organizations develop and governments seek novel
modes to deliver care, it is important to recognize that
certain complex surgical procedures need to be cen-
tralized in tertiary referral centers. With esophagec-
tomies, increased experience results not only in
decreased mortality but also in decreased hospital
charges. A strategy emphasizing centers of excellence
for esophageal resections should result in improved
outcomes for the patient and decreased charges for the
health care industry.
We thank Kenneth Hess, PhD, of Biomathematics and
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Discussion
Dr Douglas E. Wood (Seattle, Wash). Dr Swisher, I con-
gratulate you and your colleagues for the perseverance and
patience that I am sure must have been necessary to penetrate
the Medicare database in the HCUP. Physicians involved in
outcomes research recognize that the layers of bureaucracy
one must pass to access the data are far more difficult than the
data analysis itself.
One problem with these data sets is that they are fairly
crude, limiting the extent of questions that can be answered,
and require the formulation of a hypothesis around the avail-
able data. In this case the authors may have preferred to
examine the effects of individual surgeon experience on
esophagectomy outcomes but instead chose hospital volume
as a source of data that was extractable from the database.
Although outcomes analysis in cardiac operations examines
surgeon or hospital results compared with other cardiotho-
racic surgeons, general thoracic outcomes compare general
surgeons who are occasional operators in the chest to board-
certified thoracic surgeons who dedicate their practice to tho-
racic operations. Dr Carolyn Reed has already shown that
board certification in thoracic operations results in decreased
morbidity, mortality, and cost for pulmonary resections.
Similar studies in other areas have shown that increased spe-
cialization or increased volumes improve outcomes in coro-
nary artery bypass grafting, pancreatectomy, colectomy, and
breast cancer management. Outcomes research is increasing-
ly used by the government and other insurers to determine
health care policy. Because of the power of outcomes studies
to influence policy decisions, it is important that we physi-
cians take an active role in leading them, as Dr Swisher and
his colleagues have done.
Dr Swisher, I have two questions about your study. I was
puzzled by your choosing a volume of less than 5 esophagec-
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tomies per year as the definition of a low-volume hospital.
That certainly seems very low and may artificially support
your results. On what basis did you choose this number, and
have you done this same analysis with a different threshold,
for example, 20 esophagectomies per year?
Dr Swisher. As you said, the Medicare database is a diffi-
cult system to work within, and one has to accept that the
Medicare database is only picking up the Medicare
esophagectomies. At our institution that was 40% of the
patients undergoing esophagectomy. Five is therefore only a
relative number, and the actual acceptable threshold is more
on the order of 10 to 15 esophagectomies per year. We chose
the number 5 because of the recent study published in JAMA
by Begg and colleagues, in which there was significant reduc-
tion across the board when Medicare esophagectomies fell
below 5 per year. We found that the mortality rate continues
to fall as the number of esophagectomies increase so that hos-
pitals that perform 25 or more Medicare esophagectomies per
year have a mortality rate of only 2%.
Dr Wood. Second, do you think that the measurement of
hospital esophagectomy volume is actually a surrogate for
individual surgeon esophagectomy experience and that it is
the surgeon’s experience more than the institution’s that
determines the results? Is there a way that we can ask this
same question but using surgeon volumes of esophagectomy
as the variable?
Dr Swisher. That is a very interesting question because
operative mortality is based on a variety of things. It is based
on the technical experience and ability of the surgeon, but it
is also based on the surrounding hospital environment. The
experience of the hospital with esophageal operations and
postoperative care is also important. It is probably not just the
volume of the individual surgeon that is important. We are
now evaluating the importance of individual surgeon volume
by looking within our institution to see whether there are dif-
ferences within surgeons related to volume. This study would
potentially answer that question because it would look at
individual surgical volume in the same hospital environment.
Dr Wood. Your article is very valuable. It supports our
impressions that specialization and experience provide better
results at a lower cost, truly improved value in health care that
must be acknowledged by credentialing bodies and those that
reimburse for health care.
Dr Vaughn A. Starnes (Los Angeles, Calif). Dr Swisher, I
have two questions. The data suggest that, regardless of vol-
ume, the number of complications is about equal in these
institutions. In point of fact, it appeared that the likelihood of
death was related more to how these higher-volume institu-
tions cared for the complications.
Dr Swisher. Again, the Medicare database is not a perfect
database. Mortality is a very easy end point to obtain—you
can get a yes or a no. With complications, it is much more dif-
ficult to determine an end point because there are a variety of
complications, and they have not been subset into major or
minor problems. In addition, the people who are coding
esophagectomies and complications are not physicians and
often not thoroughly trained in medicine; therefore, it is dif-
ficult to count on the quality of the reported complications.
Operative mortality data are going to be very clean and very
good, but the complication data are going to be a little bit
more difficult to interpret. Nevertheless, your observation is
very interesting and supports the view that the reduced mor-
tality is due in part to hospital experience, as well as surgical
experience.
Dr Starnes. Did the type of repair, the type of reconstruc-
tion, make a difference in outcomes, for example, stomach
reconstruction versus colon reconstruction?
Dr Swisher. By using ICD-9 codes we were able to sepa-
rate out whether the patients had a total esophagectomy or a
partial esophagectomy. However, when we put that parameter
into operative mortality in our multivariate analysis, it did not
correlate with operative mortality or hospital use.
Dr Michael T. Jaklitsch (Boston, Mass). How should poli-
cy makers use these data? It seems that there is a dilemma
here. We could try to decrease the number of esophagectomies
that are being done on the community level, but that entails
many problems. People have to travel hundreds of miles to
have an esophagectomy. They are hundreds of miles away
from family and support for 17 days, and there is a 3% chance
of dying away from home. Another danger is that they will
never be offered esophagectomy because of that travel dis-
tance. The alternative is to try to credential those community
places. Can you envision a way to improve the quality of the
noncancer centers to reduce their mortality, reduce their mor-
bidity, and perhaps offer more operations to the community?
Dr Swisher. One of the problems with esophageal cancer
is that it is a relatively rare procedure. Therefore, to get the
volume needed to obtain a reduction in mortality, you really
have to have centers that do it. These centers do not have to
be cancer specialized, but they have to be high-volume cen-
ters. These data clearly demonstrate that it is not possible to
avoid an increase in mortality in hospitals in which only an
occasional esophagectomy is done. Just as in strokes with
elective carotid operations, a certain number of them must be
done at a given hospital to get the benefit of the operation. I
think the same thing is true with esophagectomies.
Regardless of the system that develops, a health maintenance
organization or whatever, it has to be recognized that these
rare complex oncologic procedures need to be centralized,
regardless of whether a community hospital or an academic
center is used. We had a problem recently in our area. Some
esophagectomies were performed in the low-volume commu-
nity centers and the outcomes were poor. The local physi-
cians saw that the patients did very badly and started to give
the patients definitive chemoradiation therapy rather than sur-
gical therapy. Therefore, I think it is very important to air the
fact that esophagectomies can be done with low morbidity,
low mortality, and decreased costs at high-volume centers.
Dr John R. Benfield (Los Angeles, Calif). I am really com-
menting equally on your presentation and on the comments of
other discussants. The fact that you got your information in a
retrospective manner from the Medicare data is important.
Now we need to validate your findings with prospective infor-
mation. In cardiac operations we have the Society of Thoracic
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 6
Swisher et al 1133
modality therapy or combined-modality therapy and was
there a preponderance of one versus the other, especially at
your institution or tertiary referral centers? My guess is that
there was a trend toward trimodality therapy, which has
increased incidences of perioperative morbidity and mortali-
ty that may make your data more significant.
Dr Swisher. Unfortunately, that is again a limitation of the
Medicare database. We are not able to delineate whether
patients received preoperative chemotherapy and radiation
therapy. We have studied that question very closely within
our own institution, as have a variety of other investigators,
and we have not been able to see any increased operative
mortality or morbidity with trimodality therapy when per-
formed in the proper setting and high-volume center. That
question is probably better answered in a single institution,
where all the variables can be controlled. It would be nice, but
it is not available in this Medicare database.
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Surgeons database, which to my knowledge is the best avail-
able information in the world. I am pleased to tell you that the
Society of Thoracic Surgeons is now working very hard to
create a general thoracic surgical database that would include
esophagectomy. This will facilitate obtaining additional infor-
mation of the kind that you have given us today.
Dr David Jablons (San Francisco, Calif). I enjoyed your
article. I might have missed one comment, and I think it is
important: if there is one consensus about how to manage
adenocarcinomas of the gastroesophageal junction, I think it
is that there is no consensus. As you mentioned, the incidence
of tumor is changing rapidly, not just in esophageal cancer
but in cancer of the thorax overall. It is especially critical, ret-
rospectively and prospectively, to try to determine how to
manage these patients, and to interpret is to control for the
multivariate therapies. My question specifically is this: Did
you look at whether these patients were receiving single-
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